NIH AMP Study underway at CAPRISA Clinic
The NIH AMP (Antibody Mediated Prevention) study, a world first, where antibodies are passively infused every 8 weeks for 10 infusions to assess if it can prevent HIV acquisition, was initiated at the eThekwini Clinic this month. The study is being run in over 15 countries in 3 continents and will enrol 4200 participants, 1500 of which are women at risk in sub-Saharan Africa.
CAPRISA is one of 15 sub-Saharan Africa sites of this study led by CAPRISA’s senior research clinician Dr Kathy Mngadi. The CAPRISA eThekwini Research Clinic enrolled their first participant on 26 May 2016; screening is in full swing to reach the target enrolment of 103 participants over the next two years.
The first participant enrolled in the AMP study receiving an infusion at the CAPRISA eThekwini Research clinic